Sofgen Pharma (PROCF) director files Form 3 initial ownership

Rhea-AI Filing Summary

Sofgen Pharma S.A. director Romero Camacho Carlos has filed an initial statement of beneficial ownership on Form 3 for the company’s shares. The available data show no reported buy, sell, or other insider transactions and no derivative positions in this filing.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Romero Camacho Carlos

(Last) (First) (Middle)

11600 MIRAMAR PARKWAY, SUITE 300

(Street)

MIRAMAR FLORIDA 33025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sofgen Pharma S.A. [ PROC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

See Exhibit 24 - Power of Attorney.

No securities are beneficially owned.

	/s/ Freddy Andres Lozano Reyes, attorney-in-fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Sofgen Pharma (PROCF) Form 3 filing report?

The Form 3 filing reports that Romero Camacho Carlos is a director of Sofgen Pharma S.A. and is disclosing his initial beneficial ownership status. The structured data show no insider transactions or derivative positions linked to this filing.

Does the Sofgen Pharma (PROCF) Form 3 show any insider share purchases or sales?

No insider share purchases or sales are shown in the provided Form 3 data. The transactions list is empty and the transaction summary records zero buy, sell, or derivative transactions, indicating this filing is purely an initial ownership disclosure.

Who is the reporting person in the Sofgen Pharma (PROCF) Form 3?

The reporting person is Romero Camacho Carlos, identified as a director of Sofgen Pharma S.A. He is not flagged as an officer or ten-percent owner in the structured data associated with this Form 3 filing.

Are there any derivative securities reported in this Sofgen Pharma (PROCF) Form 3?

No derivative securities are reported in this Form 3 data. The derivative summary is empty and the transaction summary shows zero derivative transactions or exercises, suggesting no options, warrants, or similar instruments are disclosed here.

Does the Sofgen Pharma (PROCF) Form 3 indicate gifts or tax-related share dispositions?

The Form 3 data show no gifts or tax-related share dispositions. Gift count, gift shares, tax withholding count, and tax withholding shares are all recorded as zero in the transaction summary section.